Cysteine engineered fibronectin type III domain binding molecules
Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.
1. An engineered fibronectin type III (FN3) domain peptide comprising an amino acid residue substituted with a cysteine residue at an amino acid position selected from the group consisting of residues 8, 10, 14, 15, 20, 45, 48, 54, 59, and 64, of the FN3 domain, wherein the amino acid positions of the residues of the FN3 domain correspond to the amino acid positions of SEQ ID NO: 27.
2. The engineered FN3 domain peptide of claim 1 , further comprising a half-life extending moiety.
3. The engineered FN3 domain peptide of claim 2 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), or at least a portion of an Fc region of an immunoglobulin.
4. The engineered FN3 domain peptide of claim 1 , further comprising a chemical entity conjugated to the cysteine residue.
5. An engineered fibronectin type III (FN3) domain peptide comprising an amino acid residue substituted with a cysteine residue at an amino acid position selected from the group consisting of residues 11, 16, 30, 34, 38, 40, 41, 47, 60, 62, 70, 83, 84, and 85, of the FN3 domain, wherein the amino acid positions of the residues of the FN3 domain correspond to the amino acid positions of SEQ ID NO: 27.
6. The engineered FN3 domain peptide of claim 5 , further comprising a half-life extending moiety.
7. The engineered FN3 domain peptide of claim 6 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), or at least a portion of an Fc region of an immunoglobulin.
8. The engineered FN3 domain peptide of claim 5 , further comprising a chemical entity conjugated to the cysteine residue.